Loading
Latest filing published 16 Sept 2026 for Ange Prostatype Genomics AB. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
All filings by Anders Liljeblad on record concern Ange Prostatype Genomics AB. In total, 2 filings cover trades dated 15 September 2026.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
The newest entry dates from 16 September 2026: a transaction, in Ange Prostatype Genomics AB. Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations